TBEC

TB Europe Coalition holds its third webinar

TBEC is going to conduct its third webinar in the series “Opportunities for civil society and TB communities from EECA region within the Global Fund Allocation Cycle 2020-2022”.

Webinar «Opportunities for civil society and TB communities from EECA region within the Global Fund Allocation Cycle 2020-2022»

On May 15:00 form 3 pm to 4:30 (Kyiv time) TB Europe Coalition will held the second webinar from a series of webinars – «Opportunities for civil society and TB communities from EECA region within the Global Fund Allocation Cycle 2020-2022»

TB Europe Coalition launches series of webinars on opportunities for civil society and TB communities within the Global Fund Allocation Cycle 2020-2022

TB Europe Coalition will conduct a series of webinars – “Opportunities for civil society and TB communities from EECA region within the Global Fund Allocation Cycle 2020-2022″ – to inform representatives of the civil society organizations and communities about opportunities and practical tools available to engage with and influence the national funding requests within the Global […]

Approaches that work: How civil society can join efforts with Parliamentarians to sustain political will to end TB

Do you want to make a difference? SAVE THE DATE for FREE WEBINAR to find out how to get at your members of parliament and harness political will.

TBEC/EHRA Webinar Global Fund’s Community, Rights & Gender Technical Assistance Program

“Global Fund’s Community, Rights & Gender Technical Assistance Program” webinar to inform the participants about opportunities available for NGOs and CBOs from eligible countries in EECA region through the Global Fund’s CRG Technical Assistance Program so after the webinar they could be able to initiate the request for the TA in their countries.

TBEC webinar on Sustainability, Transition, and Co-financing (STC) of Health Products

Would you like to better understand the Global Fund’s policy on Sustainability, Transition and Co-Financing of TB drugs? What is the impact of this policy on availability of TB drugs in your country? What are the key challenges and risks?